A plea for TDM-based optimisation for treatment of Crohn's disease - Authors' reply

Lancet Gastroenterol Hepatol. 2017 Feb;2(2):81-82. doi: 10.1016/S2468-1253(16)30222-9. Epub 2017 Jan 12.

Authors

Nicholas A Kennedy¹, Catriona Keerie², Craig Mowat³, Jack Satsangi⁴

Affiliations

¹ IBD Pharmacogenetics, University of Exeter, Exeter, UK. Electronic address: nick.kennedy1@nhs.net.
² Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
³ Gastrointestinal Unit, Ninewells Hospital, Dundee, UK.
⁴ Gastrointestinal Unit, Western General Hospital, Edinburgh, UK.

PMID: 28403991
DOI: 10.1016/S2468-1253(16)30222-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Crohn Disease / drug therapy*
Humans

Grants and funding